Law & Regulation
Jeffrey Finkle, CEO of Arcview, Sits in the Investor Hotseat on November 30th
Arcview CEO, Jeffrey Finkle, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments. The Arcview Group (TAG)…
Arcview CEO, Jeffrey Finkle, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments.
The Arcview Group (TAG) is an integrated financial services and asset management firm serving the cannabis, industrial hemp, and psychedelics sectors. TAG delivers these services through three operating subsidiaries, Arcview Capital, its broker/dealer, Arcview Ventures, its principal investing group, and Arcview Management Consulting, its consulting division.
TAG is known for its thought leadership delivered through live events, original content production, research, investor pitch nights, and high-profile speakerships.
TAG believes in the incredible value and opportunity, both economic and social, created by these industries. We believe in supporting diversity and inclusion, supporting minorities, marginalized communities, and gender diversification in all aspects of our service offerings.
Will Jeffrey be able to handle the heat in the hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment